Iron deficiency is a hugely understated problem affecting 30 million people in the US alone and about 1.6 billion globally. The first line of treatment is oral iron supplements that are typically associated with poor absorption and tolerability with gastrointestinal (GI) side-effects ranging from mild to severe, for eg., stomach discomfort, nausea, constipation and diarrhea, oftentimes leading to patient non-compliance. The alternative standard-of-care is intravenous (IV) iron infusion which is more invasive, riskier due to a rare possibility of an anaphylactic shock, thereby requiring a clinical setting, and hence much more expensive than oral iron. Though IV iron has a greater bioavailability, the high payload of iron entering the systemic circulation also causes moderate to severe side-effects. There is no ideal solution comprising the benefits of both orals and IV, without their respective downsides. Keylika seeks to bridge this gap with its proprietary transdermal iron. Our patch will provide superior clinical outcomes, without adverse GI side-effects, at the convenience of a patient’s home.